Loading
Capricor Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 24 Sept 2024.
Capricor Therapeutics, Inc.: what insiders have been doing
Capricor Therapeutics, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Capricor Therapeutics, Inc. logged 27 filings by 5 insiders.
Only sales appear on the open market, 11 sales in all totalling €4.5M, filed by 3 insiders. The amount is not disclosed for 6 filings. The largest single trade was a sale of €1.6M by Sabar Karimah Es, published on 1 April 2026.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
With 27 filings in twelve months, the company is more active than the median of 19 filings across the 5,814 companies we follow on the same exchange. Our records for Capricor Therapeutics, Inc. go back to 2021, with 7 purchases and 15 sales on the open market in total. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists net income at -105.0 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
62
Thresholds
n/a
Buy Volume
€14M
7 ops. · all time
Sell Volume
€874M
15 ops. · all time
Who traded when
BuySaleAnthony Bergmann4 sales
Karen Krasney4 sales
Karimah Es Sabar3 sales
Since the insiders bought
- -36.9%Entry US$10.34 · Close at T+365 US$6.52
- +584.6%Entry US$2.86 · Close at T+365 US$19.58
- +527.9%Entry US$2.83 · Close at T+365 US$17.77
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Capricor Therapeutics, Inc. Buy (bullish), based on 5 analysts. Average price target: US$27.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$7.27
Analyst consensus
5 analystsBuy
US$7.00Target US$27.00(+271%)US$54.00
Income statement
EBITDA-US$100.1M
Net income-US$105M0.0% margin
Valuation
PER (forward)-5.0x
P/Book1.7x
Beta0.61
Balance sheet & cash
Market capUS$422.7M
Total debtUS$14.5M
Free Cash Flow-US$81.5M
Debt / Equity37%
Profitability & ownership
ROE-73.7%
ROA-33.6%
% insiders9.4%
% institutions76.3%
Last declaration on 29 June 2026
Declarations62 total
24,100 sharesCommon StockSEC:0001593087-26-000013:0
24,100 sharesCommon StockSEC:0001593087-26-000013:1
24,100 sharesCommon StockSEC:0001593086-26-000012:0
24,100 sharesCommon StockSEC:0001593086-26-000012:1
500 sharesCommon StockSEC:0001593087-26-000011:0
500 sharesCommon StockSEC:0001593087-26-000011:1
400 sharesCommon StockSEC:0001593087-26-000011:2
400 sharesCommon StockSEC:0001593087-26-000011:3
500 sharesCommon StockSEC:0001593086-26-000010:0
500 sharesCommon StockSEC:0001593086-26-000010:1
400 sharesCommon StockSEC:0001593086-26-000010:2
400 sharesCommon StockSEC:0001593086-26-000010:3
3,937 shares@ US$1.390.0013% mcap1.6% of flowCommon StockSEC:0001310715-26-000004:0
7,529 shares@ US$3.180.6% of flowCommon StockSEC:0001873796-26-000006:0
7,529 shares@ US$32.005.6% of flowCommon StockSEC:0001873796-26-000006:1
25,000 shares@ US$3.189.5% of flowCommon StockSEC:0001593087-26-000005:0
25,000 shares@ US$30.126189.7% of flowCommon StockSEC:0001593087-26-000005:1
693 shares@ US$1.390.1% of flowCommon StockSEC:0001593086-26-000006:0
21,488 shares@ US$3.749.0% of flowCommon StockSEC:0001593086-26-000006:1
2,819 shares@ US$3.181.0% of flowCommon StockSEC:0001593086-26-000006:2
61,265 shares@ US$4.866.9% of flowCommon StockSEC:0001873796-26-000004:0
61,265 shares@ US$30.16842.6% of flowCommon StockSEC:0001873796-26-000004:1
25,000 shares@ US$30.117484.6% of flowCommon StockSEC:0001593086-26-000006:3
53,735 shares@ US$4.866.0% of flowCommon StockSEC:0001873796-26-000004:2
53,735 shares@ US$31.026838.4% of flowCommon StockSEC:0001873796-26-000004:3
25 of 62 declarations
About Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc. is a US-listed biopharmaceutical company trading on the NASDAQ in the United States. Headquartered in San Diego, California, the company focuses on cell-based and exosome-based therapeutics for rare diseases, with an emphasis on high-unmet-need neuromuscular and inflammatory conditions. Capricor’s corporate identity has been shaped by a science-driven development model built on academic partnerships, and by a strategy that prioritizes differentiated biologics rather than large-volume commercial drugs. The company’s evolution into its current public structure followed a merger completed in 2013, and it has since remained a development-stage biotech with increasing industrial readiness as it moves closer to potential commercialization.
The company’s lead asset is Deramiocel, formerly known as CAP-1002, a cell therapy being developed primarily for Duchenne muscular dystrophy-associated cardiomyopathy. Capricor is positioning Deramiocel as a potentially disease-modifying therapy aimed at both cardiac and functional outcomes, which is central to its investment thesis. Beyond Duchenne, the company has signaled broader neuromuscular potential, including Becker muscular dystrophy, and has also highlighted exosome-related science and anti-fibrotic, immunomodulatory mechanisms as part of its platform. This gives Capricor a relatively focused but scientifically differentiated pipeline, anchored in rare disease biology and translational medicine.
Read moreShow less
From a competitive perspective, Capricor operates in a niche but highly competitive segment of biotechnology. It is not a broad pharma company; instead, it competes with other advanced-therapy developers pursuing gene, cell, and regenerative approaches in rare disease. That creates a binary, high-upside profile, but also exposes the company to clinical, regulatory, manufacturing, and financing risks that are typical of specialty biotech. Its San Diego manufacturing footprint is strategically important because commercial success in cell therapy depends not only on clinical efficacy but also on GMP manufacturing consistency and supply-chain execution.
Recent company developments have been meaningful. In 2025 and 2026, Capricor reported continued regulatory progress on the Deramiocel BLA, with the FDA review active and a PDUFA target action date of August 22, 2026. The company also cited positive HOPE-3 Phase 3 data, including functional and cardiac endpoints, which helped support the program’s clinical profile. On the operational side, Capricor expanded manufacturing space at its San Diego headquarters to prepare for a possible launch. Financially, the company strengthened its balance sheet through capital raises in 2025, improving runway into 2027 based on management disclosure. For international investors, CAPR is best viewed as a NASDAQ-listed United States biotech story driven by clinical milestones, regulatory execution, and the transition from late-stage development to potential commercialization.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
